The serum immunoglobulin G glycosylation signature of gastric cancer

EuPA Open Proteomics

Volumn 6, Issue , 2015, Pages 1-9

  Ruhaak, L Renee ^a   Barkauskas, Donald A ^b   Torres, Javier ^c   Cooke, Cara L ^d   Wu, Lauren D ^a   Stroble, Carol ^a   Ozcan, Sureyya ^a   Williams, Cynthia C ^a   Camorlinga, Margarita ^c   Rocke, David M ^d,e   Lebrilla, Carlito B ^a,d   Solnick, Jay V ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e University of California Davis   (United States)

Author keywords

Duodenal ulcer; Gastric cancer; Gastritis; N glycan; Nano LC MS; Serum

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; CANCER DIAGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DUODENUM ULCER; FEMALE; GASTRITIS; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NANO LIQUID CHROMATOGRAPHY WITH TIME OF FLIGHT MASS SPECTROMETRY; NON ATROPHIC GASTRITIS; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; STOMACH CANCER; TIME OF FLIGHT MASS SPECTROMETRY;

EID: 84920918340     PISSN: 22129685     EISSN: 22129685     Source Type: Journal    
DOI: 10.1016/j.euprot.2014.11.002     Document Type: Article

References (52)

1. Fuchs C.S., Mayer R.J. Gastric carcinoma. N Engl J Med 1995, 333:32-41.
2. Catalano V., Labianca R., Beretta G.D., Gatta G., de Braud F., Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 2005, 54:209-241.
3. Dicken B.J., Bigam D.L., Cass C., Mackey J.R., Joy A.A., Hamilton S.M. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005, 241:27-39.
4. de Martel C., Ferlay J., Franceschi S., Vignat J., Bray F., Forman D., et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13:607-615.
5. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64:31-49.
6. Correa P., Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007, 133:659-672.
7. Parsonnet J., Friedman G.D., Vandersteen D.P., Chang Y., Vogelman J.H., Orentreich N., et al. Helicobacter pylori infection and the risk of gastric-carcinoma. N Engl J Med 1991, 325:1127-1131.
8. Ohta H., Noguchi Y., Takagi K., Nishi M., Kajitani T., Kato Y. Early gastric carcinoma with special reference to macroscopic classification. Cancer 1987, 60:1099-1106.
9. Packer N.H., von der Lieth C.W., Aoki-Kinoshita K.F., Lebrilla C.B., Paulson J.C., Raman R., et al. Frontiers in glycomics: bioinformatics and biomarkers in disease. An NIH white paper prepared from discussions by the focus groups at a workshop on the NIH campus, Bethesda MD (September 11-13, 2006). Proteomics 2008, 8:8-20.
10. Callewaert N., Van Vlierberghe H., Van Hecke A., Laroy W., Delanghe J., Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004, 10:429-434.
11. Parekh R.B., Dwek R.A., Sutton B.J., Fernandes D.L., Leung A., Stanworth D., et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985, 316:452-457.
12. van de Geijn F.E., Wuhrer M., Selman M.H., Willemsen S.P., de Man Y.A., Deelder A.M., et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther 2009, 11:R193.
13. Ruhaak L.R., Uh H.W., Beekman M., Hokke C.H., Westendorp R.G., Houwing-Duistermaat J., et al. Plasma protein N-glycan profiles are associated with calendar age, familial longevity and health. J Proteome Res 2011, 10:1667-1674.
14. Knezevic A., Gornik O., Polasek O., Pucic M., Redzic I., Novokmet M., et al. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology 2010, 20:959-969.
15. Vanhooren V., Desmyter L., Liu X.E., Cardelli M., Franceschi C., Federico A., et al. N-glycomic changes in serum proteins during human aging. Rejuvenation Res 2007, 10:521-531.
16. Hua S., An H.J., Ozcan S., Ro G.S., Soares S., DeVere-White R., et al. Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers. Analyst 2011, 136:3663-3671.
17. Kirmiz C., Li B.S., An H.J., Clowers B.H., Chew H.K., Lam K.S., et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics 2007, 6:43-55.
18. Arnold J.N., Saldova R., Galligan M.C., Murphy T.B., Mimura-Kimura Y., Telford J.E., et al. Novel glycan biomarkers for the detection of lung cancer. J Proteome Res 2011, 10:1755-1764.
19. Saldova R., Fan Y., Fitzpatrick J.M., Watson R.W., Rudd P.M. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 2011, 21:195-205.
20. Ruhaak L.R., Miyamoto S., Lebrilla C.B. Developments in the identification of glycan biomarkers for the detection of cancer. Mol Cell Proteomics 2013, 12:846-855.
21. Ozcan S., Barkauskas D.A., Ruhaak L.R., Torres J., Cooke C.L., An H.J., et al. Serum glycan signatures of gastric cancer. Cancer Prev Res (Phila) 2014, 7:226-235.
22. Huhn C., Selman M.H., Ruhaak L.R., Deelder A.M., Wuhrer M. IgG glycosylation analysis. Proteomics 2009, 9:882-913.
23. Selman M.H.J., Niks E.H., Titulaer M.J., Verschuuren J.J.G.M., Wuhrer M., Deelder A.M. IgG Fc N-glycosylation changes in Lambed-Eaton myasthenic syndrome and myasthenia gravis. J Proteome Res 2011, 10:143-152.
24. Bondt A., Selman M.H., Deelder A.M., Hazes J.M., Willemsen S.P., Wuhrer M., et al. Association between galactosylation of immunoglobulin g and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J Proteome Res 2013, 12:4522-4531.
25. Selman M.H., de Jong S.E., Soonawala D., Kroon F.P., Adegnika A.A., Deelder A.M., et al. Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics 2012;, 11:. M111 014563.
26. Shikata K., Yasuda T., Takeuchi F., Konishi T., Nakata M., Mizuochi T. Structural changes in the oligosaccharide moiety of human IgG with aging. Glycoconj J 1998, 15:683-689.
27. Yamada E., Tsukamoto Y., Sasaki R., Yagyu K., Takahashi N. Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconj J 1997, 14:401-405.
28. Ruhaak L.R., Uh H.W., Beekman M., Koeleman C.A., Hokke C.H., Westendorp R.G., et al. Decreased levels of bisecting GlcNAc glycoforms of IgG are associated with human longevity. PLoS ONE 2010, 5:e12566.
29. Alley W.R., Vasseur J.A., Goetz J.A., Svoboda M., Mann B.F., Matei D.E., et al. N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res 2012, 11:2282-2300.
30. Qian Y., Wang Y., Zhang X., Zhou L., Zhang Z., Xu J., et al. Quantitative analysis of serum IgG galactosylation assists differential diagnosis of ovarian cancer. J Proteome Res 2013.
31. Kodar K., Stadlmann J., Klaamas K., Sergeyev B., Kurtenkov O., Immunoglobulin G. Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J 2012, 29:57-66.
32. Ruhaak L.R., Deelder A.M., Wuhrer M. Oligosaccharide analysis by graphitized carbon liquid chromatography-mass spectrometry. Anal Bioanal Chem 2009, 394:163-174.
33. Chu C.S., Ninonuevo M.R., Clowers B.H., Perkins P.D., An H.J., Yin H., et al. Profile of native N-linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time-of-flight mass spectrometry. Proteomics 2009, 9:1939-1951.
34. Ruhaak L.R., Taylor S.L., Miyamoto S., Kelly K., Leiserowitz G.S., Gandara D., et al. Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Anal Bioanal Chem 2013, 405:4953-4958.
35. Dixon M.F., Genta R.M., Yardley J.H., Correa P. Classification and grading of gastritis. The updated Sydney System. Am J Surg Pathol 1996, 20:1161-1181.
36. Torres J., Leal-Herrera Y., Perez-Perez G., Gomez A., Camorlinga-Ponce M., Cedillo-Rivera R., et al. A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico. J Infect Dis 1998, 178:1089-1094.
37. Wuhrer M., Stam J.C., van de Geijn F.E., Koeleman C.A., Verrips C.T., Dolhain R.J., et al. Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. Proteomics 2007, 7:4070-4081.
38. Kronewitter S.R., de Leoz M.L., Peacock K.S., McBride K.R., An H.J., Miyamoto S., et al. Human serum processing and analysis methods for rapid and reproducible N-glycan mass profiling. J Proteome Res 2010, 9:4952-4959.
39. Packer N.H., Lawson M.A., Jardine D.R., Redmond J.W. A general approach to desalting oligosaccharides released from glycoproteins. Glycoconj J 1998, 15:737-747.
40. Kronewitter S.R., An H.J., de Leoz M.L., Lebrilla C.B., Miyamoto S., Leiserowitz G.S. The development of retrosynthetic glycan libraries to profile and classify the human serum N-linked glycome. Proteomics 2009, 9:2986-2994.
41. Hrydziuszko O., Viant M.R. Missing values in mass spectrometry based metabolomics: an undervalued step in the data processing pipeline. Metabolomics 2011, 8:161-174.
42. Benjamini Y., Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc B: Met 1995, 57:289-300.
43. Miller R. Simultaneous statistical inference 1981, Springer-Verlag.
44. Porras C., Nodora J., Sexton R., Ferreccio C., Jimenez S., Dominguez R.L., et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control 2013, 24:209-215.
45. Knezevic A., Polasek O., Gornik O., Rudan I., Campbell H., Hayward C., et al. Variability, heritability and environmental determinants of human plasma N-glycome. J Proteome Res 2009, 8:694-701.
46. Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061.
47. Walker M.R., Lund J., Thompson K.M., Jefferis R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J 1989, 259:347-353.
48. Kumpel B.M., Rademacher T.W., Rook G.A., Williams P.J., Wilson I.B. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum Antibodies Hybridomas 1994, 5:143-151.
49. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: a magic bullet. Science 2013, 339:286-291.
50. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
51. Parekh R.B., Roitt I.M., Isenberg D.A., Dwek R.A., Ansell B.M., Rademacher T.W. Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet 1988, 1:966-969.
52. Moore J.S., Wu X., Kulhavy R., Tomana M., Novak J., Moldoveanu Z., et al. Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. AIDS 2005, 19:381-389.